Flag of the European Union EU Clinical Trials Register Help

Clinical trials for celltrion

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    68 result(s) found for: celltrion. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2019-003518-15 Sponsor Protocol Number: CT-P6_4.2 Start Date*: 2020-03-10
    Sponsor Name:Celltrion, Inc.
    Full Title: A Follow-Up Study of Long-Term Efficacy of Patients with HER2-Positive Early Breast Cancer Who Had Been Enrolled in Study CT-P6 4.2
    Medical condition: Long-term safety and efficacy of treatment with CT-P6 (Herzuma) in HER-2 positive early breast cancer patients
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: PL (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2020-004463-25 Sponsor Protocol Number: RHMMED1716 Start Date*: 2020-12-15
    Sponsor Name:University Hospital Southampton NHS Trust
    Full Title: SWitching InflixiMab to SUbcut from Intravenous Therapy
    Medical condition: Crohn's Disease Ulcerative Colitis Rheumatoid Arthritis Psoriatic Arthritis Ankylosing Spondylitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2013-004497-10 Sponsor Protocol Number: CT-P13-3.4 Start Date*: 2014-07-16
    Sponsor Name:Celltrion, Inc.
    Full Title: A Randomized, Double-Blind, Parallel-Group, Phase 3 Study to Demonstrate Noninferiority in Efficacy and to Assess the Safety of CT-P13 Compared to Remicade in Patients With Active Crohn’s Disease
    Medical condition: Active Crohn's Disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004856 10058815 Crohn's disease acute episode LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) HU (Completed) GB (Completed) IT (Completed) ES (Completed) RO (Completed) DK (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2019-001087-30 Sponsor Protocol Number: CT-P13_3.8 Start Date*: 2019-07-25
    Sponsor Name:Celltrion, Inc
    Full Title: A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of the Subcutaneous Injection of CT-P13 (CT-P13 SC) as Maintenance Therapy in Patients With Moderat...
    Medical condition: Moderately to Severely Active Crohn’s Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) CZ (Completed) SK (Completed) FR (Completed) PL (Completed) DE (Completed) GR (Completed) HU (Completed) ES (Completed) AT (Completed) BG (Completed) HR (Completed) IT (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2022-002336-31 Sponsor Protocol Number: CT-P17-3.3 Start Date*: 2022-10-20
    Sponsor Name:CELLTRION, Inc
    Full Title: A Randomized, Active-Controlled, Double-Blind, Phase 3 Study to Compare Pharmacokinetics, Efficacy, and Safety of CT-P17 with Humira in Patients with Moderate to Severe Chronic Plaque Psoriasis
    Medical condition: Moderate to Severe Chronic Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003849-15 Sponsor Protocol Number: CT-P13_3.7 Start Date*: 2020-04-03
    Sponsor Name:Celltrion, Inc.
    Full Title: A Randomized, Placebo Controlled, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of the Subcutaneous Injection of CT-P13 (CT-P13 SC) as Maintenance Therapy in Patients with Moderat...
    Medical condition: Moderately to Severely Active Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) AT (Prematurely Ended) BG (Completed) ES (Prematurely Ended) CZ (Completed) PL (Completed) GR (Prematurely Ended) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-003401-60 Sponsor Protocol Number: CT-P59_3.1 Start Date*: 2020-09-30
    Sponsor Name:CELLTRION, Inc.
    Full Title: A Phase 2/3, Randomized, Parallel-Group, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of CT-P59 in Combination with Standard of Care in Hospitalized Patients with SARS...
    Medical condition: Novel severe acute respiratory syndrome coronavirus 2 (SARS CoV 2) infection
    Disease: Version SOC Term Classification Code Term Level
    23.0 10022891 - Investigations 10084271 SARS-CoV-2 test positive PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: RO (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-002098-25 Sponsor Protocol Number: ZKSJ0137_INFLIXCOVID Start Date*: 2021-05-27
    Sponsor Name:Friedrich-Schiller-Universität Jena
    Full Title: A randomized, controlled, multicenter, open label phase II clinical study to evaluate infliximab in the treatment of patients with severe COVID-19 disease (INFLIXCOVID)
    Medical condition: severe COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001690-25 Sponsor Protocol Number: CT-P17-3.1 Start Date*: 2018-11-13
    Sponsor Name:Celltrion, Inc
    Full Title: A Randomized, Active-Controlled, Double-Blind, Phase 3 Study to Compare Efficacy and Safety of CT-P17 with Humira when Co-administered with Methotrexate in Patients with Moderate to Severe Active R...
    Medical condition: Moderate to Severe Active Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) LT (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-000660-25 Sponsor Protocol Number: CT-P17_3.2 Start Date*: 2019-07-09
    Sponsor Name:CELLTRION, Inc.
    Full Title: A Phase III, Open-label, Single-arm, Multiple-dose Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients with Moderate to Severe Active Rheumatoid Arthritis
    Medical condition: Moderate to Severe Active Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-001045-39 Sponsor Protocol Number: CT-P43_3.1 Start Date*: 2020-11-12
    Sponsor Name:Celltrion, Inc
    Full Title: A Randomized, Active-Controlled, Double-Blind, Phase 3 Study to Compare the Efficacy and Safety of CT-P43 to Stelara in Patients with Moderate to Severe Plaque Psoriasis
    Medical condition: Moderate to Severe Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed)
    Trial results: View results
    EudraCT Number: 2021-002369-17 Sponsor Protocol Number: 2021-01 Start Date*: 2021-07-22
    Sponsor Name:GETAID
    Full Title: Management of moderate POstoperative recurrence in Crohn's disease: a randoMizEd contROLled trial, the POMEROL trial.
    Medical condition: Crohn's disease patients having an i2 endoscopic postoperative recurrence 6-12 months after ileocolonic anastomosis.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000952-36 Sponsor Protocol Number: CT-P39_3.1 Start Date*: 2021-02-05
    Sponsor Name:CELLTRION, Inc.
    Full Title: A Double-blind, Randomized, Active-controlled, Parallel Group, Phase 3 Study to Compare Efficacy and Safety of CT-P39 and Xolair in Patients With Chronic Spontaneous Urticaria Who Remain Symptomati...
    Medical condition: Chronic Spontaneous Urticaria
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10072757 Chronic spontaneous urticaria PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) PL (Completed) BG (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2020-004278-23 Sponsor Protocol Number: CT-P42_3.1 Start Date*: 2021-03-16
    Sponsor Name:CELLTRION Inc.
    Full Title: A Randomized, Active-Controlled, Double-Masked, Parallel-Group, Phase 3 Study to Compare Efficacy and Safety of CT-P42 in Comparison with Eylea in Patients with Diabetic Macular Edema
    Medical condition: Diabetic Macular Edema
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10057934 Diabetic macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SK (Completed) HU (Completed) CZ (Completed) PL (Completed) LT (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2018-002147-28 Sponsor Protocol Number: CT-P16_3.1 Start Date*: 2018-12-10
    Sponsor Name:CELLTRION, Inc.
    Full Title: A Double-Blind, Randomized, Active-Controlled, Parallel-Group, Phase 3 Study to Compare Efficacy and Safety of CT-P16 and EU-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non...
    Medical condition: Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10079440 Non-squamous non-small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) HU (Completed) BG (Completed) PL (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2013-004493-96 Sponsor Protocol Number: CT-P10-3.3 Start Date*: 2014-03-21
    Sponsor Name:CELLTRION, Inc.
    Full Title: A Phase 1/3, Randomised, Parallel-Group, Active-Controlled, Double-Blind Study to Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan, E...
    Medical condition: Advanced Follicular Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016910 Follicle centre lymphoma, follicular grade I, II, III stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016909 Follicle centre lymphoma, follicular grade I, II, III stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) ES (Completed) GR (Completed) IT (Completed) PT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2013-004525-84 Sponsor Protocol Number: CT-P6-3.2 Start Date*: 2014-04-03
    Sponsor Name:CELLTRION, Inc.
    Full Title: A Phase 3, Double-Blind, Randomized, Parallel-Group, Active-Controlled Study to Compare the Efficacy and Safety of CT-P6 and Herceptin as Neoadjuvant and Adjuvant Treatment in Patients with HER2-Po...
    Medical condition: Her-2 Positive Early Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: LV (Completed) GR (Completed) HU (Completed) ES (Completed) IT (Completed) PT (Completed) RO (Completed) PL (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2011-004468-31 Sponsor Protocol Number: CT-P13-3.2 Start Date*: 2012-01-06
    Sponsor Name:CELLTRION, Inc
    Full Title: An Open-Label, Single-Arm, Extension Study to Demonstrate Long-Term Efficacy and Safety of CT-P13 When Co-administered With Methotrexate in Patients With Rheumatoid Arthritis Who Were Treated With ...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) AT (Completed) ES (Completed) LV (Completed) SK (Completed) LT (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-005974-91 Sponsor Protocol Number: CT-P41_3.1 Start Date*: 2021-04-26
    Sponsor Name:Celltrion, Inc
    Full Title: A Double-blind, Randomized, Active-controlled, Phase 3 Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety of CT-P41 and US-licensed Prolia in Postmenopausal Women with Osteop...
    Medical condition: Osteoporosis is a systemic skeletal disease that is characterized by low bone mass and micro architectural deterioration of bone tissue, with a low bone mineral density (BMD) and consequent increas...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10031285 Osteoporosis postmenopausal PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: LV (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2017-003150-16 Sponsor Protocol Number: COUP-1 Start Date*: 2018-11-21
    Sponsor Name:University Hospital Ulm
    Full Title: Copanlisib and Rituximab in Marginal Zone Lymphoma Patients
    Medical condition: Marginal Zone Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062113 Splenic marginal zone lymphoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076596 Marginal zone lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) AT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 05:33:45 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA